Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Accumulated Expenses (2016 - 2025)

Coherus Oncology's Other Accumulated Expenses history spans 13 years, with the latest figure at $11.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 44.31% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $11.2 million, down 44.31%, while the annual FY2025 figure was $11.2 million, 44.31% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $11.2 million at Coherus Oncology, up from $7.1 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $20.0 million in Q4 2024 and bottomed at $3.5 million in Q4 2021.
  • The 5-year median for Other Accumulated Expenses is $10.6 million (2022), against an average of $11.2 million.
  • The largest annual shift saw Other Accumulated Expenses plummeted 71.33% in 2021 before it surged 204.52% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $3.5 million in 2021, then soared by 204.52% to $10.6 million in 2022, then dropped by 28.27% to $7.6 million in 2023, then soared by 162.56% to $20.0 million in 2024, then crashed by 44.31% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Accumulated Expenses are $11.2 million (Q4 2025), $7.1 million (Q3 2025), and $20.0 million (Q4 2024).